Pietro Musso

Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial

Sandro Pignata, Giovanni Scambia, Gabriella Ferrandina et al. · Journal of Clinical Oncology · 2011 · 227 citations · Full text

Medicine, Oncology, Pharmacology +13

Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: Results from the SOCRATES retrospective study

Sandro Pignata, Gabriella Ferrandina, Giovanna Scarfone et al. · Critical Reviews in Oncology/Hematology · 2009 · 31 citations

Medicine, Gynecology, Oncology +17

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

Sandro Pignata, Giovanni Scambia, Antonella Savarese et al. · BMC Cancer · 2006 · 24 citations · Full text

Medicine, Oncology, Pharmacology +17

Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): Activity and safety results of the MITO-2 randomized multicenter trial

Sandro Pignata, Giovanni Scambia, Antonella Savarese et al. · Journal of Clinical Oncology · 2009 · 16 citations

Medicine, Oncology, Pharmacology +13

Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): Final analysis of the MITO-2 randomized multicenter trial.

Sandro Pignata, Giovanni Scambia, Antonella Savarese et al. · Journal of Clinical Oncology · 2010 · 10 citations

Medicine, Oncology, Pharmacology +13